While I don't believe that's true, a presentation of what's been achieved at UCLA should be big, even if it's only in a Phase 1/2 Trial. I really don't think a statement from the company would be as big unless it announces an event occurring, like submission to a regulator, or approval of the EDEN. Otherwise I believe the company will get some attention when they hold an Annual Meeting and update us on the many things that otherwise we just speculate about.
A reiteration of the Phase 3 trial will do little unless it's tied to what's been done at UCLA beyond it. A presentation on the compassionate use of DCVax-L in the UK could be big if it actually reported on how many patients have received it, what types of cancers, and some idea of what was observed in the various forms of cancer. It should be clear that nothing cures all who receive it, DCVax-L may have been administered to people who otherwise would go into hospice care and barring a miracle are no longer with us. The point is, observations could be made whether DCVax-L cured the patient or not, it could tell us a lot about the use of DCVax-L as a tumor agnostic product.
Gary
Market Data 
Markets 
AI
